GLFD Guilford Pharmaceuticals (MM)

Guilford Pharmaceuticals to Present at Harris Nesbitt Gerard Healthcare Conference BALTIMORE, Dec. 10 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. announced today that it will present at the Harris Nesbitt Gerard Healthcare Conference in New York on Thursday, December 11, 2003 at 8:30 a.m., E.S.T. To access a live audio webcast of the Company's presentation, please visit the 'Investors' section of Guilford's website at http://www.guilfordpharm.com/ approximately 10 minutes before the start of the presentation. The audio webcast will be accessible under either the 'presentations' or 'conferences' sections of the Investor portion of the website. About Guilford Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post-prostatectomy erectile dysfunction. Contact: Guilford Pharmaceuticals Inc. Stacey Jurchison 410.631.5022 Internet addresses: http://www.guilfordpharm.com/ DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison, Guilford Pharmaceuticals Inc., +1-410-631-5022, Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright